Qlife Holding AB (publ)

Stockholm Stock Exchange QLIFE.ST

Qlife Holding AB (publ) Free Cash Flow for the year ending December 31, 2023: USD -6.18 M

Qlife Holding AB (publ) Free Cash Flow is USD -6.18 M for the year ending December 31, 2023, a 28.60% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Qlife Holding AB (publ) Free Cash Flow for the year ending December 31, 2022 was USD -8.66 M, a -48.90% change year over year.
Qlife Holding AB (publ) Free Cash Flow for the year ending December 31, 2021 was USD -5.82 M, a -9.90% change year over year.
Qlife Holding AB (publ) Free Cash Flow for the year ending December 31, 2020 was USD -5.29 M, a -739.80% change year over year.
Qlife Holding AB (publ) Free Cash Flow for the year ending December 31, 2019 was USD -630.07 K.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Stockholm Stock Exchange: QLIFE.ST

Qlife Holding AB (publ)

CEO	Mr. Thomas Warthoe
IPO Date	March 2, 2020
Location	Sweden
Headquarters	Redaregatan 48
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

Key trends

Past 5 years